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Antiapoptotic Bcl-2 family proteins inhibit apoptosis in cultured cells by binding BH3 domains of proapoptotic Bcl-2
family members via a hydrophobic BH3 binding groove on the protein surface. We investigated the physiological
importance of the BH3 binding groove of an antiapoptotic Bcl-2 protein in mammals in vivo by analyzing a viral Bcl-2
family protein. We show that the c-herpesvirus 68 (cHV68) Bcl-2 family protein (cHV68 v-Bcl-2), which is known to
inhibit apoptosis in cultured cells, inhibits both apoptosis in primary lymphocytes and Bax toxicity in yeast. Nuclear
magnetic resonance determination of the cHV68 v-Bcl-2 structure revealed a BH3 binding groove that binds BH3
domain peptides from proapoptotic Bcl-2 family members Bax and Bak via a molecular mechanism shared with host
Bcl-2 family proteins, involving a conserved arginine in the BH3 peptide binding groove. Mutations of this conserved
arginine and two adjacent amino acids to alanine (SGR to AAA) within the BH3 binding groove resulted in a properly
folded protein that lacked the capacity of the wild-type cHV68 v-Bcl-2 to bind Bax BH3 peptide and to block Bax
toxicity in yeast. We tested the physiological importance of this v-Bcl-2 domain during viral infection by engineering
viral mutants encoding a v-Bcl-2 containing the SGR to AAA mutation. This mutation resulted in a virus defective for
both efficient reactivation of cHV68 from latency and efficient persistent cHV68 replication. These studies demonstrate
an essential functional role for amino acids in the BH3 peptide binding groove of a viral Bcl-2 family member during
chronic infection.
Citation: Loh J, Huang Q, Petros AM, Nettesheim D, van Dyk LF, et al. (2005) A surface groove essential for viral Bcl-2 function during chronic infection in vivo. PLoS Pathog
1(1): e10.
Introduction
Bcl-2 family proteins are important regulators of cell death
and other aspects of cell physiology such as glycolysis and
calcium metabolism [1–5]. The Bcl-2 family can be divided
into antiapoptotic proteins, which have in common four Bcl-
2 homology domains (BH1–4), and proapoptotic proteins,
which have either BH1–3 domains or only a BH3 domain [2–
4,6–8]. A key mechanism by which this family regulates cell
death in cultured cells involves a binding interaction between
a hydrophobic groove on the surface of the antiapoptotic
family protein and the BH3 domain of proapoptotic family
members [2–4,9–13]. Furthermore, the importance of BH3
binding domains of antiapoptotic proteins has been shown in
vivo in nematodes [14,15]. However, antiapoptotic Bcl-2
family proteins also interact with proteins outside of the
Bcl-2 family, such as Aven, Apaf-1, Btf, Beclin1, Raf-1,
calcineurin, tissue transglutaminase, FAST, and p53 [6,16–
26]. The structural basis for interactions between these
proteins and Bcl-2 family members, and the functional
signiﬁcance of these interactions, is less well understood
than the structural basis and functional importance of
interactions among Bcl-2 family members.
Certain viruses have acquired during evolution host genes
that confer selective advantages. Viral proteins encoded by
these genes often retain or even enhance advantageous
functions of their host counterparts and lose functions that
do not beneﬁt the virus. Importantly, many viruses encode
antiapoptotic Bcl-2 family proteins [7,27,28]. For example,
viral Bcl-2 family proteins are encoded by all c-herpesviruses,
including the human viruses Epstein-Barr virus (EBV) and
Kaposi’s sarcoma-associated herpesvirus (KSHV), and the
murine virus c-herpesvirus 68 (cHV68) [7,27].
The conservation of v-Bcl-2 genes across the c-herpesvi-
ruses suggests that these proteins play an important and
evolutionarily conserved role in the pathogenesis of c-
herpesvirus infection. EBV, KSHV, and cHV68 all latently
infect B cells [29–31], reactivate from latency, persistently
replicate in both normal and immunocompromised hosts,
and induce B cell lymphomas during chronic infection ([32]
and unpublished data). The capacity to establish and
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lifelong infection that is characteristic of c-herpesviruses. In
addition, the capacity to persistently replicate at a low level
despite the presence of active host immunity is a critically
important aspect of c-herpesvirus pathogenesis. Persistent
replication contributes to viral spread from chronically
infected hosts to new hosts, and may well contribute to
tumorigenesis [33–35].
An in vivo role during infection has been demonstrated
only for the cHV68 v-Bcl-2 [36]. The cHV68 v-Bcl-2 protein
has been shown to inhibit apoptosis induced by Fas, TNFa,
and Sindbis virus infection [37–39]. It is expressed during
latency and has critical roles in reactivation from latency, the
capacity to persistently replicate in immunocompromised
mice such as those lacking interferon-c (IFNc), and in
determining the number of latent cells early after infection
[36,40,41]. Surprisingly, the cHV68 v-Bcl-2 has no role during
acute infection of ﬁbroblast cells in vitro or in vivo [36].
These data suggest that viral regulation of apoptosis is more
important during chronic than acute cHV68 infection.
Further support for this concept comes from studies showing
that proapoptotic host molecules such as perforin, gran-
zymes, and caspase 3 are unimportant during acute cHV68
infection but are critically important for limiting the amount
of latent cHV68 infection [42,43]. Together, these data
suggest that regulation of apoptosis by host and viral genes
plays a critical role speciﬁc to chronic cHV68 infection.
These observations demonstrate a physiological role for a
v-Bcl-2 family member in reactivation from viral latency and
in persistent replication. The molecular mechanisms respon-
sible for this role in vivo can be deﬁned by evaluating the
phenotypes of viruses expressing mutant forms of the v-Bcl-2
protein. We reasoned that analysis of a viral Bcl-2 protein
using a combination of structural, biochemical, and patho-
genesis studies would reveal whether viral and host Bcl-2
family members might function via the same mechanisms,
and would clarify the importance of those mechanisms
during infection. In this study, we identiﬁed the structure
and biochemical function of a domain in cHV68 v-Bcl-2
predicted to be important for v-Bcl-2 function, and then
tested the role of this domain in vivo. The cHV68 v-Bcl-2
shared with host antiapoptotic Bcl-2 family proteins the
capacity to block apoptosis in primary lymphocytes induced
by antigen receptor signaling, corticosteroids, and c-irradi-
ation, and to inhibit Bax toxicity in yeast. Solving the three-
dimensional structure of the v-Bcl-2 revealed a functional
hydrophobic surface groove that binds Bax and Bak BH3
peptides via a mechanism shared with host anti-apoptotic
Bcl-2 family members. Mutations within this BH3 binding
groove signiﬁcantly decreased binding afﬁnity for Bax
peptide, abrogated inhibition of Bax toxicity in yeast, and
ablated v-Bcl-2 function during chronic infection. These
studies are the ﬁrst to identify a speciﬁc domain of a viral Bcl-
2 family protein that is essential for a physiological activity in
vivo.
Results
cHV68 v-Bcl-2 Inhibits Apoptosis Induced by Diverse
Apoptotic Stimuli in Primary Lymphocytes
The cHV68 v-Bcl-2 has been shown to block apoptosis in
cultured cells in response to several proapoptotic stimuli [37–
39]. We evaluated the antiapoptotic activity of the cHV68 v-
Bcl-2 in vivo in primary cells by generating transgenic mice
expressing v-Bcl-2 in thymocytes under the control of the lck
proximal promoter (Figure 1A). While this approach can
Figure 1. Transgenic Expression of v-Bcl-2 in Thymocytes
(A) Schematic illustration of the cHV68 genome, v-Bcl-2 genomic region,
and transgene construct.
(B) Real-time RT-PCR quantitation of v-Bcl-2 expression in transgenic
thymocytes (left) and splenocytes (right).
(C) Total number of thymocytes in v-Bcl-2 transgenic and nontransgenic
mice.
(D) Percentage of CD4 or CD8 single-positive, double-positive (DP) and
double-negative (DN) thymocytes in v-Bcl-2 transgenic and nontrans-
genic mice.
DOI: 10.1371/journal.ppat.0010010.g001
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Synopsis
Viruses can manipulate their hosts by expressing proteins that
structurally and functionally resemble host cellular proteins. One
important cellular process manipulated by viruses is apoptosis, a cell
death program that is regulated by a family of Bcl-2-like
proapoptotic and antiapoptotic proteins. Gammaherpesviruses
encode Bcl-2 family proteins (v-Bcl-2) that may contribute to their
ability to cause tumors and persist for the lifetime of their hosts. The
authors solved the structure of the murine c-herpesvirus 68 (cHV68)
v-Bcl-2 and found that it is similar to cellular antiapoptotic proteins
and that v-Bcl-2 uses the same mechanism as cellular Bcl-2 to bind
to peptides from proapoptotic Bcl-2 family proteins. Furthermore,
they found that a cHV68 virus expressing a mutated form of v-Bcl-2
that cannot bind to peptides from proapoptotic Bcl-2 family
proteins is defective in its ability to cause chronic viral infection in
mice. Thus, a specific structural feature and molecular mechanism of
the v-Bcl-2 that is shared with host antiapoptotic Bcl-2 proteins is
important for the function of this protein during viral infection.
These findings enhance our understanding of the molecular
mechanisms of chronic c-herpesvirus infection, and suggest that
targeting the functions of the v-Bcl-2 protein might have
therapeutic benefit.determine the effect of only ectopically expressed v-Bcl-2 in
T lymphocytes, it has been successfully used to show the
activity of both Bcl-2 and Bcl-xL in primary cells in vivo
[44,45]. An added advantage of this system is the ability to
study the activity of the v-Bcl-2 using multiple well-
characterized lymphotoxic stimuli that have been shown to
induce apoptotic cell death [46–51]. No antibodies for the
cHV68 v-Bcl-2 are available, so we used quantitative RT-PCR
to demonstrate speciﬁc cHV68 v-Bcl-2 mRNA expression in
two transgenic mouse lines (v-Bcl-2A and v-Bcl-2B). v-Bcl-2A
mice had 4- to 6-fold higher v-Bcl-2 expression in thymus and
spleen than v-Bcl-2B mice (Figure 1B).
cHV68 v-Bcl-2 transgenic mice had higher numbers of
total thymocytes than nontransgenic mice (Figure 1C),
consistent with an effect of v-Bcl-2 on cell survival. However,
v-Bcl-2 transgenic mice displayed no abnormalities in CD4
and CD8 T cell development in the thymus (Figures 1D and
S1), nor were there any alterations in thymic architecture
(unpublished data). Additionally, v-Bcl-2 transgenic thymo-
cytes did not survive longer in explant culture than control
cells (unpublished data). We next determined whether
cHV68 v-Bcl-2 inhibits cell death induced by three diverse
apoptotic stimuli in vivo. cHV68 v-Bcl-2 transgenic double-
positive thymocytes were signiﬁcantly more resistant than
control thymocytes to apoptosis induced by dexamethasone,
c-irradiation, and CD3e ligation (Figures 2 and S1). The
increase in survival of transgenic double-positive thymocytes
exceeds, and is therefore not attributable to, the slight
increase in total thymocyte number in transgenic mice.
Transgenic thymocytes from v-Bcl-2A mice were more
resistant to dexamethasone than those from v-Bcl-2B mice,
particularly at the highest doses of dexamethasone, con-
sistent with higher levels of expression of v-Bcl-2 in these
cells (see Figure 1B). No depletion of double-positive
thymocytes was observed in transgenic or nontransgenic
mice treated with vehicle or isotype antibody controls
(unpublished data).
These results are similar to those previously found using
host Bcl-2 and Bcl-xL transgenic mice [44,45,52] and show
that the cHV68 v-Bcl-2 shares with its cellular counterparts
the capacity to inhibit apoptosis induced by diverse proa-
poptotic stimuli in primary thymocytes. Together with
previous studies in cultured cells [37–39], these data strongly
support the concept that the cHV68 v-Bcl-2 blocks apoptosis
by targeting a step or steps common to the death programs
triggered by multiple cellular signals.
cHV68 v-Bcl-2 Is Structurally Homologous to Bcl-2 and
Bcl-xL
The cHV68 v-Bcl-2 has limited amino acid homology to
host Bcl-2 family proteins outside of the BH1 domain.
Therefore, to understand the molecular basis of v-Bcl-2
function and the relationship between the cHV68 v-Bcl-2 and
host Bcl-2 family members, we expressed and puriﬁed the
protein and determined its structure by nuclear magnetic
resonance (NMR) spectroscopy. For structural studies, we
expressed amino acids 1–137 of the v-Bcl-2, removing the
carboxy-terminal hydrophobic domain. The overall fold of v-
Bcl-2 (Figure 3) was very similar to that of Bcl-xL (Figure 3B)
[53] and other Bcl-2 family proteins [2]. The core of v-Bcl-2
was formed by two predominantly hydrophobic central
helices, a5 and a6, which were ﬂanked on one side by a3
Figure 2. v-Bcl-2 Inhibits Cell Death in Thymocytes
(A) Survival of DP thymocytes from v-Bcl-2A (left) and v-Bcl-2B (right) mice 48 h following intraperitoneal injection with various doses of
dexamethasone.
(B and C) Survival of DP thymocytes from v-Bcl-2A and v-Bcl-2B mice 48 h following (B) 250 rads of c-irradiation and (C) intraperitoneal injection with 30
lg of anti-CD3e antibody.
DOI: 10.1371/journal.ppat.0010010.g002
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minimized coordinates for the cHV68 v-Bcl-2 have been
deposited with the Protein Data Bank (PDB [http://www.rcsb.
org/pdb/] accession code 2ABO).
v-Bcl-2 clearly contained structural elements correspond-
ing to the BH1, BH2, BH3, and BH4 regions of Bcl-xL, despite
the fact that the v-Bcl-2 BH4 region was not readily apparent
in sequence alignments with Bcl-xL (Figure 3D). The BH1
region (in magenta) was composed of the carboxy-terminal
end of a4, the loop connecting a4t oa5, and the amino-
terminal end of a5. The BH2 region (in red; Figure 3D) was
composed of a7, and the BH3 (in green) and BH4 (in yellow)
regions were composed of a2 and a1, respectively. The two
side chain conformations of Trp10 in a1 generated two
distinct sets of resonances for residues in this region, and the
resonances corresponding to the predominant conformation
were used for these analyses. One notable difference between
the cHV68 and KSHV v-Bcl-2 proteins and host antiapoptotic
Bcl-2 family proteins is the lack of an extended loop between
a1 and a2, which in host Bcl-2 contains sites for caspase
cleavage and regulatory phosphorylation [1,2,54].
An alignment revealing the structural and amino acid
conservation between Bcl-2, Bcl-xL, the cHV68 v-Bcl-2, and
the KSHV v-Bcl-2 proteins is shown in Figure 3D. Aside from
the lack of the a1/a2 loop in the v-Bcl-2, this structural
alignment reveals how a similar overall structure relates to
relatively poor amino acid homology in regions outside of the
BH1 domain. This striking conservation of structure between
v-Bcl-2 and other Bcl-2 family members, despite only low-
level amino acid homology outside of the BH1 domain,
supports the concept that strong evolutionary pressure has
led to retention of the overall structure, and suggests that the
mechanisms of v-Bcl-2 action might therefore be similar to
those of its cellular counterparts.
cHV68 v-Bcl-2, Like Antiapoptotic Host Bcl-2 Family
Proteins, Has a Hydrophobic Surface Groove and Binds
BH3 Peptides from Proapoptotic Bcl-2 Family Members
cHV68 v-Bcl-2 had an elongated surface hydrophobic
groove composed of amino acid residues from a2, a3, a4,
and a5, similar to the groove observed on Bcl-2 and Bcl-xL
(Figures 3C and S2). The orientation of a3 and a4 deﬁned the
bottom of this groove, which is the predicted binding site for
BH3 domains of proapoptotic Bcl-2 family proteins [2,53].
Conservation of this hydrophobic groove in the cHV68 v-Bcl-
2 suggests that it may, like host Bcl-2, bind BH3 domains of
proapoptotic Bcl-2 family proteins. One approach to deﬁning
the biochemical properties of the surface groove of an
antiapoptotic Bcl-2 family member is to measure the afﬁnity
of the protein for BH3 peptides from proapoptotic Bcl-2
Figure 3. Solution Structure of cHV68 v-Bcl-2
(A and B) Ribbon representation of (A) cHV68 v-Bcl-2 and (B) Bcl-xL with BH1, BH2, BH3, and BH4 regions in magenta, red, green, and yellow,
respectively. Helices are numbered with respect to Bcl-xL.
(C) Connolly surface for cHV68 v-Bcl-2 calculated using a probe radius of 1.4 A ˚. Residues are colored as follows: Leu, Val, Ile, Phe, Tyr, Trp, Met, and Ala in
yellow; Arg, Lys, and His in blue; Asp and Glu in red; all others in gray. The hydrophobic groove is indicated by an arrow.
(D) Structural and sequence alignment of KSHV and cHV68 v-Bcl-2 proteins with Bcl-2 and Bcl-xL.
DOI: 10.1371/journal.ppat.0010010.g003
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Role of Viral Bcl-2 BH1 Domain In Vivofamily members [2–4]. For example, the BH3 domain of Bak is
necessary and sufﬁcient for effecting cell death, and
mutations in Bak BH3 peptide that reduce binding to Bcl-
xL also abrogate interaction of full-length Bak with Bcl-xL
[55,56].
We therefore used NMR to analyze binding of BH3
peptides from proapoptotic Bcl-2 family proteins Bax, Bak,
and Bad to puriﬁed cHV68 v-Bcl-2. We focused on Bak and
Bax, since cHV68 v-Bcl-2 blocks apoptosis induced by diverse
stimuli (see Figure 2), and Bak and Bax are essential for cell
death induced by many stimuli [57–59]. We selected the Bad
BH3 peptide for analysis since Bad is a potently proapoptotic
BH3-only Bcl-2 family member that induces cell death via
interaction with antiapoptotic Bcl-2 family members [8]. Both
Bax and Bak peptides were in slow exchange with cHV68 v-
Bcl-2 on the NMR timescale, indicating Kd values of less than
5 lM. In contrast, Bad BH3 peptide bound weakly to cHV68
v-Bcl-2, with a Kd of greater than 300 lM. cHV68 v-Bcl-2
therefore differs signiﬁcantly from Bcl-2 and Bcl-xL, which
bind the Bad BH3 peptide with an afﬁnity of 0.6–15 nM [9].
These results show that the cHV68-v-Bcl2 binds BH3 peptides
from some, but not all, BH3 domain containing proapoptotic
Bcl-2 family members.
A Common Mechanism for Binding of BH3 Peptides by
cHV68 v-Bcl-2 and Bcl-xL
The retention of a hydrophobic groove and the capacity to
bind BH3 peptides by cHV68 v-Bcl-2 suggested that cHV68 v-
Bcl-2 shares with Bcl-2 and Bcl-xL a common capacity for
binding BH3 peptides. However, the lack of Bad BH3 peptide
binding led us to question whether the mechanism of BH3
peptide binding is shared between host Bcl-2 family proteins
and the cHV68 v-Bcl-2. To directly address this question, we
used nuclear Overhauser effect (NOE) experiments (Figure 4).
We found that the Bak BH3 peptide bound to cHV68 v-Bcl-2
and Bcl-xL in the same orientation ([53] and unpublished
data), with contact occurring primarily between hydrophobic
residues of v-Bcl-2 and Bak peptide. cHV68 v-Bcl-2 residues
with NOE contacts to the Bak peptide (Figure 4A) were
structurally homologous to those in the complex of Bcl-xL
and Bak peptide, in which Arg139 of Bcl-xL forms a key
contact with Asp83 of the Bak peptide [53].
Arg139 is highly conserved among Bcl-2 family proteins,
and mutation of Asp83 in the Bak peptide to alanine (D83A)
reduces its afﬁnity for Bcl-xL by more than 120-fold. The
cHV68 v-Bcl-2 residue that is structurally homologous to
Arg139 of Bcl-xL is Arg87, which is a conserved amino acid in
the v-Bcl-2 BH1 domain (see Figure 3D). We tested the
importance of this Arg:Asp interaction in the binding of
cHV68 v-Bcl-2 to Bak peptide in an NMR-based titration of v-
Bcl-2 with D83A mutant Bak peptide. We observed no
binding of D83A mutant Bak peptide to cHV68 v-Bcl-2 over
the concentration range of the titration, indicating a Kd of
more than 300 lM. Thus, Arg87 of cHV68 v-Bcl-2 played a
key role, similar to that of Bcl-xL Arg139, in binding to Asp83
of the Bak BH3 peptide. These data show that the molecular
mechanisms of BH3 peptide binding are shared between
cHV68 v-Bcl-2 and host antiapoptotic proteins.
Residues in the cHV68 v-Bcl-2 BH3 Binding Groove Are
Required for v-Bcl-2 Binding to BH3 Peptides and
Inhibition of Bax Toxicity in Yeast
The conservation of the mechanism by which cHV68 and
host Bcl-2 family members bind BH3 peptides suggested that
the cHV68 v-Bcl-2 would also inhibit the function of
proapoptotic Bcl-2 family members. We tested this hypoth-
esis using a Bax toxicity assay in yeast (Figure 4). Inhibition of
Bax toxicity in yeast by Bcl-2 family proteins depends on
amino acids within the BH3 binding groove of the anti-
apoptotic family member and, at least in part, on hetero-
dimerization with Bax [60–63].
The cHV68 v-Bcl-2 inhibited Bax-mediated death as
effectively as Bcl-2 (Figure 4B). No inhibition of Bax-
mediated death was observed in empty vector control
transformations (unpublished data). Because structural data
suggested the importance of the v-Bcl-2 Arg87, we tested the
effect of mutating Arg87 and two adjacent residues (i.e.,
Ser85-Gly86-Arg87; in magenta in Figure 4A) to alanine
Figure 4. Mutagenesis of cHV68 v-Bcl-2 BH3 Binding Groove
(A) Ribbon representation of cHV68 v-Bcl-2 showing residues that contact Bak peptide (in green and R87) and the SGR residues that were mutated (in
magenta).
(B) Growth of yeast following transformation with the indicated constructs (above, bar graph) and Western blot of SGR/AAA and wild-type v-Bcl-2 from
transformed yeast (below, blot).
(C) Overlay of the
15N-HSQC spectra of SGR/AAA (red contours) and wild-type (black contours) v-Bcl-2 showing conservation of structure between
mutant and wild-type proteins.
DOI: 10.1371/journal.ppat.0010010.g004
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inhibit Bax-mediated death. Mutations in this region have
been shown to alter the antiapoptotic activity of both host
and other viral Bcl-2 proteins [3,4,7,27]. We mutated all three
amino acids based on preliminary studies demonstrating
partial effects of single mutations in this region (unpublished
data). The SGR/AAA mutation abrogated cHV68 v-Bcl-2
inhibition of Bax-mediated toxicity in yeast despite equiv-
alent expression levels of wild-type and SGR/AAA mutant v-
Bcl-2 protein (Figure 4B). Moreover, SGR/AAA mutant
cHV68 v-Bcl-2 bound Bax peptide at least 1500-fold less well
than wild-type cHV68 v-Bcl-2, as measured by NMR (Kd of
greater than 300 lM compared to less than 5 lM for wild-type
cHV68 v-Bcl-2). Analogous mutations in Bcl-2 and Bcl-xL
similarly abrogate antiapoptotic activity and binding to
proapoptotic proteins [64,65]. Importantly, a comparison of
the
15N- heteronuclear single-quantum coherence (HSQC)
spectra of wild-type and SGR/AAA mutant cHV68 v-Bcl-2
conﬁrmed that SGR/AAA mutant v-Bcl-2 retains the overall
fold of wild-type v-Bcl-2 (Figure 4C), indicating that func-
tional defects in SGR/AAA mutant cHV68 v-Bcl-2 are
attributable speciﬁcally to alterations in the BH3 binding
groove rather than to misfolding of the mutant protein. Thus,
residues that lie in the cHV68 v-Bcl-2 BH3-binding groove
were essential for both binding of Bax BH3 peptide and for
inhibition of Bax-mediated toxicity in yeast.
A Functional BH3 Binding Groove Is Essential for Efficient
Reactivation of cHV68 from Latency and for Persistent
cHV68 Replication
The conservation of the structure and function of the
cHV68 v-Bcl-2 BH3 binding groove led us to hypothesize that
this groove, and the conserved Arg87 required for interaction
with BH3 peptides from proapoptotic Bcl-2 proteins and for
inhibition of Bax toxicity in yeast, would be essential for the
function of the v-Bcl-2 in vivo during cHV68 infection. To
test this hypothesis, we compared the phenotypes of wild-type
cHV68 virus, a cHV68 virus lacking the entire v-Bcl-2 due to a
Figure 5. SGR/AAA Mutant Viruses Replicate Normally In Vitro and In Vivo
(A) Shown are schematic illustrations of the genomes of cHV68, v-cyclin.LacZ, and SGR/AAA mutant viruses with the engineered PstI site underlined,
and v-Bcl-2 containing the SGR/AAA mutation.
(B) Southern blot of cHV68, v-cyclin.LacZ, and SGR/AAA mutant viruses. Expected bands (kb) for PstI/BamHI digest: cHV68, 1.5, 1.3, and 1.2; v-
cyclin.LacZ, 1.3, 1.2, 1.1, and 0.05; and SGR/AAA, 1.5, 1.2, 0.8, and 0.6. Expected bands (kb) for PstI/HindIII digest: cHV68, 7.5, 1.2, 0.9, and 0.4; v-
cyclin.LacZ, 7.1, 4.3, 1.2, 0.9, 0.4, and 0.07; and SGR/AAA, 7.5, 1.2, 0.6, 0.39, and 0.36.
(C) Multistep growth curves of SGR/AAA mutants and cHV68.
(D) Acute splenic titers at 4 or 9 dpi from mice infected with SGR/AAA mutants.
DOI: 10.1371/journal.ppat.0010010.g005
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[36], and cHV68 viruses expressing the SGR/AAA mutant
form of the v-Bcl-2.
We generated two independent isolates of cHV68 contain-
ing the SGR/AAA mutation in the M11 gene (SGR/AAA.1 and
SGR/AAA.2; Figure 5A and 5B). SGR/AAA v-Bcl-2 mutant
viruses displayed normal growth in ﬁbroblast cells in vitro
(Figure 5C), and replicated normally in the spleen (Figure 5D)
and liver (unpublished data) of infected mice at 4 and 9 d
post-infection (dpi). These results were expected, because the
Dv-Bcl-2 cHV68 mutant virus, which lacks v-Bcl-2 expression,
also exhibits completely normal replication during acute
infection [36]. Together, these data indicate that the v-Bcl-2
does not have an essential function during cHV68 acute
infection. The use of two independently generated mutants to
analyze the phenotype attributable to the SGR/AAA mutation
is an accepted standard in the ﬁeld [36,66–68]. The equivalent
phenotypes of SGR/AAA.1 and SGR/AAA.2 in multiple assays
argues against the possibility that these phenotypes are due to
chance mutations elsewhere in the viral genome.
As the Dv-Bcl-2 mutant cHV68 virus has defects in
reactivation from latency and in persistent replication [36],
we tested the effects of the SGR/AAA v-Bcl-2 mutation on
chronic cHV68 infection of IFNc
 /  mice. IFNc
 /  mice clear
acute cHV68 infection normally [42,69], but exhibit increases
in persistent replication and in the efﬁciency with which
latently infected cells reactivate virus ex vivo [36,42]. Both Dv-
Bcl-2 and SGR/AAA mutant cHV68 viruses exhibited small
but statistically signiﬁcant decreases in the frequency of cells
that reactivate from viral latency ex vivo compared to wild-
type cHV68 (Figure 6, Table 1). Furthermore, SGR/AAA
mutant cHV68 viruses, like the Dv-Bcl-2 mutant cHV68 virus,
showed no persistent replication at 42 dpi (Figure 6B, Table
1). The effect of the SGR/AAA v-Bcl-2 mutation on persistent
cHV68 virus replication was signiﬁcant, but less than the
effect of a null mutation in the gene at 16 dpi. This partial
phenotype was not due to reversion of the mutation in vivo,
since 20 individual SGR/AAA mutant cHV68 viruses present
in these mice were conﬁrmed to have the mutation by
nucleotide sequencing (unpublished data). Together, these
data demonstrate that amino acids that are critical for the
capacity of cHV68 v-Bcl-2 to bind BH3 peptides via the BH3
binding groove are essential for optimal reactivation from
latency and for the capacity to persistently replicate in tissues
Figure 6. SGR/AAA Mutant Viruses Exhibit Defects in Chronic Infection In Vivo
Ex vivo reactivation (A) and persistent replication (B) of cHV68, Dv-Bcl-2, or SGR/AAA mutant viruses at 16 or 42 dpi of IFNc
 /  mice. No significant
differences were observed between the two independent isolates of SGR/AAA mutants, and data from these two groups were pooled.
DOI: 10.1371/journal.ppat.0010010.g006
Table 1. Summary of Chronic Infection Results
Virus 16 dpi 42 dpi
Reactivation Persistent
Replication
Reactivation Persistent
Replication
cHV68 1/100 1/6,040 1/346 1/25,650
Dv-Bcl-2 1/221
a ,1/40,000
a 1/1,048
a ,1/40,000
a
SGR/AAA 1/187
a 1/23,730
a 1/2,136
a ,1/40,000
a
Frequencies of cells that reactivate virus ex vivo and are persistently infected are shown for infection of IFNc
 / mice
with cHV68 or mutant viruses.
aStatistically significant differences compared to cHV68.
DOI: 10.1371/journal.ppat.0010010.t001
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Discussion
In this study, we combined structural and biochemical
approaches to identify a BH3 peptide binding groove on the
surface of the cHV68 v-Bcl-2 protein and amino acids within
this groove that are essential for the capacity of the v-Bcl-2 to
bind BH3 peptides. These same amino acids are essential for
the capacity of the cHV68 v-Bcl-2 to block cell death in yeast
induced by expression of the proapoptotic Bcl-2 family
protein Bax, and for the contribution of the v-Bcl-2 to two
fundamentally important aspects of cHV68 pathogenesis:
reactivation from viral latency and persistent replication.
Together, these data show that this domain of the v-Bcl-2 is
essential for function in vivo, and support the concept that
the cHV68 v-Bcl-2 functions in vivo by binding BH3 domains
of antiapoptotic Bcl-2 family members.
Presence of a Functional BH3 Binding Groove on cHV68 v-
Bcl-2
We found that the cHV68 v-Bcl-2 shares with Bcl-2, Bcl-xL,
and the KSHV v-Bcl-2 a BH3 binding groove [9]. Each of these
proteins interacts with BH3 peptides from Bak and Bax, but
the viral proteins differ from the host proteins in their
inability to bind the Bad BH3 peptide [2,9]. Interestingly, the
preference for Bak and Bax peptides over BH3 peptides from
other proapoptotic family members is also seen for the
adenovirus v-Bcl-2 [7].
These differences in BH3 peptide speciﬁcity between viral
and host proteins have implications for how v-Bcl-2 proteins
inhibit apoptosis. Some models of antiapoptotic Bcl-2 family
protein function require that they heterodimerize with BH3-
only proteins such as Bad in order to sequester these
proapoptotic molecules away from Bak and Bax [3,4,57,59].
While we have not examined binding of BH3 peptides from
BH3-only proteins other than Bad, the striking lack of
binding of Bad BH3 peptide to cHV68 v-Bcl-2 suggests that
the viral protein may not use this mechanism. Instead, these
data support an alternative model that has also been
proposed for cellular antiapoptotic Bcl-2 family proteins,
but that is not generally accepted [3,4]. In this model, the
antiapoptotic proteins directly target Bax and Bak rather
than sequestering BH3-only proteins.
An interesting question is why KSHV and cHV68 v-Bcl-2
proteins bind the BH3 peptide from Bad with much lower
afﬁnity than is observed for Bcl-2 or Bcl-xL [9]. In this
property, the cHV68 and KSHV v-Bcl-2 proteins resemble
cellular Mcl-1, which also fails to bind Bad BH3 peptide and is
important for development of B cells, one of the cell types in
which cHV68 establishes latency [70,71]. One possible
explanation for the lack of binding to the Bad BH3 peptide
is that v-Bcl-2 binding to Bad is detrimental to the virus. Bad
was recently found to be essential for assembly of a
holoenzyme that regulates mitochondrial respiration, and
Bad deﬁciency results in defects in glycolysis and in aberrant
glucose homeostasis [5]. Thus, v-Bcl-2 proteins may bind
poorly to Bad, and perhaps other BH3-only Bcl-2 family
proteins, to avoid interfering with functions of BH3 domain
containing proteins in cellular processes other than induc-
tion of apoptosis. This would be important for a virus, such as
cHV68, that expresses the v-Bcl-2 in latently infected cells
[40], and would presumably beneﬁt by not having v-Bcl-2
interfere with cellular processes essential for cell viability.
cHV68 v-Bcl-2 Inhibits Apoptosis Induced by a Wide Array
of Proapoptotic Stimuli
c-herpesviruses maintain latent infection in lymphocytes
for the life of the host, and must survive in the face of the
immune response that effectively clears acute infection.
These viruses then reactivate from latency and productively
infect cells, yielding low levels of infectious virus in tissues, a
process we refer to as persistent replication. It seems
reasonable to speculate that latently infected cells may be
exposed to multiple different proapoptotic stimuli over time.
Furthermore, during the process of reactivation and persis-
tent replication, infected cells are likely subjected to immune
attack by lymphocytes that use proapoptotic cytokines or
granule contents to kill infected cells. It is therefore not
surprising that a protein such as the cHV68 v-Bcl-2, which is
important during chronic infection, has the capacity to
inhibit cell death induced by a wide variety of different
stimuli, including antigen receptor crosslinking, cortico-
steroids, and c-irradiation. In addition to the studies
presented here, observations in cultured cells show that the
cHV68 v-Bcl-2 inhibits apoptosis induced by TNFa, Fas, and
Sindbis virus infection [37–39]. While it is possible that the
cHV68 v-Bcl-2 utilizes different mechanisms to inhibit each
of these death induction pathways, it is more reasonable to
conclude that the viral protein inhibits a step in the death
execution pathway common to all of these stimuli. In this
regard, the capacity of the cHV68 v-Bcl-2 to bind BH3
peptides from Bax and Bak and to inhibit Bax-induced cell
death in yeast is of particular interest. Bax and Bak are
essential for induction of apoptosis through multiple path-
ways, and function therefore as a common gateway to the
downstream steps in cell death execution [57–59]. Targeting
these proteins would therefore have the advantage of
protecting the infected cell from diverse proapoptotic insults.
Targeting Bax and Bak may be a common strategy for many
viruses, since Bax and Bak are required for apoptosis during
adenovirus infection, and the adenovirus v-Bcl-2 E1B 19K
targetsBakandBaxforantiapoptoticfunctioninculturedcells
[7,72,73]. Furthermore, we believe that this is likely a general
mechanism, since a role for BH1-domain amino acids in
binding BH3 peptides has also been demonstrated for the
adenovirus v-Bcl-2 and the African swine fever virus v-Bcl-2
family protein A179L [7]. Given the overall poor amino acid
homology between viral Bcl-2 proteins and cellular Bcl-2
family members, the conservation of a mechanism for BH3
peptide binding between cellular and viral Bcl-2 family
proteins strongly supports the hypothesis that this property
of the v-Bcl-2 is important for function. This concept is
supported by data provided here demonstrating the essential
roleofthisdomaininthefunctionofthecHV68v-Bcl-2invivo.
Is the Critical In Vivo Role of Amino Acids in the BH3
Binding Groove Explained by v-Bcl-2 Binding to
Proapoptotic Bcl-2 Family Proteins?
We found that amino acids in the BH3 binding groove of
the cHV68 v-Bcl-2 are essential for in vivo function of the v-
Bcl-2 protein. The major known function of the BH3 binding
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2 family proteins, providing the basis for our conclusion that
our data are consistent with a role for this biochemical
function of v-Bcl-2 during chronic infection. However, there
are other potential explanations for our results. It is possible
that binding of BH3 domains is important for function, but
that binding Bcl-2 family members is not. For example, non-
Bcl-2 family proteins can contain BH3-like domains [16,17],
and it is possible that the cHV68 Bcl-2 functions by binding
to these proteins rather than to Bcl-2 family proteins.
Alternatively, the portion of the BH3 peptide binding
groove that we mutated in the studies presented here might
interact with other proteins that do not contain BH3
domains. Support for this possibility comes from the
structure of the EBV v-Bcl-2 BHRF1, which is antiapoptotic
but does not have an intact BH3 binding groove and does not
measurably bind BH3 peptides [10]. It is possible that this v-
Bcl-2, which lacks a BH3 binding groove, inhibits apoptosis by
a mechanism distinct from that used by the cHV68 and KSHV
v-Bcl-2 proteins, both of which have functional BH3 binding
grooves. For example, the EBV v-Bcl-2 might inhibit
apoptosis via interactions with other proteins such as Aven,
Apaf-1, Btf, Beclin1, Raf-1, calcineurin, tissue transglutami-
nase, FAST, or p53 [6,16–26], all of which have been shown or
suggested to to interact with host antiapoptotic Bcl-2 family
members. Perhaps a capacity to interact with one or more of
these proteins despite the SGR/AAA mutation explains the
partial phenotype of the SGR/AAA mutant cHV68 viruses in
persistent replication observed 16 dpi. It will be interesting to
compare the antiapoptotic mechanisms of the cHV68 and
KSHV v-Bcl-2 proteins with that of BHRF1 in order to
determine whether interaction with proteins that do not
contain BH3 is important for v-Bcl-2 function.
Differences between Host and Viral Antiapoptotic
Proteins
While cHV68 v-Bcl-2 shares an overall fold with its host
counterparts, there are differences between the cHV68 v-Bcl-
2 and host Bcl-2 family members, most notably the absence of
a long loop between a1 and a2 [2]. Interestingly, the KSHV
and EBV v-Bcl-2 proteins also lack this loop [9,10]. In cellular
Bcl-2 family proteins, this loop contains sites for caspase
cleavage and regulatory phosphorylation [1,2,54], and a
portion of the loop has been predicted to be involved in
p53 binding [19].
In contrast to host Bcl-2 family proteins [54,74], the KSHV
and EBV v-Bcl-2 proteins are resistant to caspase cleavage
[27,37], a process that generates proapoptotic products.
Although cHV68 v-Bcl-2 also has a shortened a1/a2 loop, it
does contain a caspase cleavage site (LDCV; see Figure 3D)
and can be cleaved by caspases [37]. However, the predicted
cleavage product does not have proapoptotic activity [37].
The absence of the a1/a2 loop in KSHV v-Bcl-2 also confers
resistance to regulatory phosphorylation by the KSHV v-
cyclin-CDK6 complex, which inactivates Bcl-2 [75,76]. Based
on its structure, the cHV68 v-Bcl-2 is also expected to be
refractory to regulatory phosphorylation. Thus, our struc-
tural analysis of the cHV68 v-Bcl-2 provides additional
evidence that v-Bcl-2 proteins have evolved strategies to
protect themselves from host cell regulatory mechanisms.
The lack of an intact a1/a2 loop in v-Bcl-2 proteins decreases
their susceptibility to inactivation via caspase cleavage or
phosphorylation, an evolutionary strategy that we and others
[2,6,7] speculate provides an advantage for the viruses by
removing the antiapoptotic function of viral Bcl-2 family
proteins from host cell control.
Implications for Control of Chronic c-Herpesvirus Infection
Mostofthediseaseburdenofhumanc-herpesvirusinfection
occurs during chronic infection. Studies here demonstrating
that amino acids in the BH3 binding groove of the v-Bcl-2 are
essential for chronic viral infection raise the possibility that
pharmacologic inhibition of v-Bcl-2 BH3 binding groove
function might inhibit chronic infection. There may be
sufﬁcient differences between viral and host proteins’ BH3
binding grooves to allow speciﬁc targeting of v-Bcl-2 proteins.
Therefore,v-Bcl-2 proteinsmayprovidea suitabletherapeutic
target for preventing or ameliorating c-herpesvirus disease.
Materials and Methods
Animals. Mice were housed and bred in a speciﬁc pathogen-free
environment at Washington University School of Medicine in
accordance with all federal and university policies. v-Bcl-2 transgenic
mice were generated as previously described [77]. Brieﬂy, the v-Bcl-2
ORF (genome coordinates 103418–103930 bp) was PCR-ampliﬁed and
ligated into the BamHI site of the p1017 vector containing the hGH
enhancer and the lck proximal promoter [78,79]. The construct was
conﬁrmed by DNA sequencing, and the DNA fragment used for
microinjection was isolated by SpeI restriction digest followed by gel
puriﬁcation. B6 embryo manipulations were performed as previously
described [77]. Transgene-positive F1 mice were identiﬁed by PCR
and conﬁrmed by Southern blot (unpublished data). Mice were
maintained as heterozygotes on the B6 background and were
genotyped by PCR using primers speciﬁc for the hGH enhancer
within the transgene construct [77]. Nontransgenic littermates were
used as negative controls for v-Bcl-2 transgenic mice. IFNc
 / mice on
the B6 background were obtained from Jackson Laboratories (Bar
Harbor, Maine, United States) and bred at Washington University. B6
mice were purchased from Jackson Laboratories. All studies were
performed using age- and sex-matched mice between 8 and 12 wk of
age.
Quantitative RT-PCR. Thymi and spleens from euthanized mice
were disrupted over a 100 lm Nytex ﬁlter to generate single-cell
suspensions. Total RNA was prepared from dissociated cells, and 2 lg
was used in reverse transcription reactions to generate cDNA
template for quantitative real-time PCR. Six replicate reactions of
real-time PCR were performed per sample using a BioRad iCycler
(BioRad, Hercules, California, United States) [80]. v-Bcl-2 speciﬁc
primers were 59-TAACATTGACCCAGGAGTTTAG-39 and 59-
CGAGGTGAAAAGTTTGGAC-39, and control reactions utilized
primers speciﬁc for 18S RNA. No positive signal was detected in
RNA samples to which reverse transcriptase was not added
(unpublished data). Three transgene-positive mice from each founder
line were analyzed, and nontransgenic samples consisted of one
transgene-negative mouse from each founder line. v-Bcl-2 message
copy number was calculated from a standard curve generated using
10
1 to 10
5 copies of a plasmid containing v-Bcl-2, and was normalized
to 18S RNA levels.
Flow cytometry. Dissociated thymocytes were pre-incubated with
anti-CD32/CD16 antibodies (Caltag Laboratories, Burlingame, Cal-
ifornia, United States; #MM7400) and stained with FITC-conjugated
anti-CD4 (Pharmingen, San Diego, California, United States;
#09424A) and tricolor-conjugated anti-CD8a (Caltag, #RM2206)
antibodies. Cells were washed, ﬁxed, and analyzed on a FACS Calibur.
Data were analyzed using CellQuest (Becton Dickinson, Palo Alto,
California, United States) and represent the mean 6 SEM from at
least two independent experiments. Statistical signiﬁcance was
determined using the Mann-Whitney test.
Bax toxicity in yeast. Yeast strain W303 was a generous gift from S.
Zheng. Murine Bax and Bcl-2 clones were generous gifts from S.
Korsmeyer. Bax was cloned into p425 GPD (ATCC, Manassas,
Virginia, United States; #87359) and Bcl-2 was cloned into p426
GPD (ATCC #87361). SGR/AAA mutant v-Bcl-2 was generated using
the ExSite PCR-Based Site-Directed Mutagenesis Kit (Stratagene, La
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amino-terminal HA-tagged and cloned into p426 GPD. All constructs
were veriﬁed by DNA sequencing, and 1 lg of each construct was used
to transform yeast using the lithium acetate method. The number of
colonies were counted 3 d following plating on selection media and is
expressed as a percentage of that for a control transformation with
p425 GPD and p426 GPD empty vectors. Transformations of yeast
with each single construct resulted in growth only on the appropriate
selection media (unpublished data). Data represent the mean 6 SEM
from four independent experiments, and statistical signiﬁcance was
determined using the Mann-Whitney test. For Western blots, total
protein from transformed yeast was prepared using Y-PER Yeast
Protein Extraction Reagent (Pierce Biotechnology, Rockford, Illinois,
United States), resolved on an SDS-PAGE gel, and detected with an
anti-HA antibody (Covance, Princeton, New Jersey, United States;
#MMS-101P).
Cell culture and viruses. NIH 3T12 cells and MEFs were cultured in
DMEM containing 10% fetal calf serum (D10). SGR/AAA mutant
viruses were generated by homologous recombination as previously
described [36]. Brieﬂy, a targeting construct was generated by
replacing wild-type v-Bcl-2 sequence with that for the SGR/AAA
mutant in pL3700, which contains a 3,723-bp BamHI/BsrGI fragment
of the cHV68 genome (genome coordinates 101,654–105,377 bp). The
mutation generates a new PstI restriction site, which was used to
distinguish wild-type from SGR/AAA viruses by Southern blot. The
targeting construct was veriﬁed by DNA sequencing and cotrans-
fected into 3T12 cells with viral DNA from v-cyclin.LacZ, which
contains a LacZ expression cassette inserted into the adjacent v-
cyclin ORF [81]. Recombinant ‘‘white’’ viruses were isolated following
X-Gal staining and screened by Southern blot for the SGR/AAA
mutation in v-Bcl-2. Two independent isolates were generated from
separate cotransfections, and each isolate was subjected to three
rounds of plaque puriﬁcation. Fifteen individual plaques from each
isolate were genotyped by Southern blot to conﬁrm the absence of
contamination with either wild-type or parental v-cyclin.LacZ viruses
(unpublished data), and one of the tested plaques was used to
generate virus stocks of each isolate. cHV68 clone WUMS (ATCC
VR1465), Dv-Bcl-2 [36], and SGR/AAA mutants were subcultured and
titered by plaque assay on 3T12 cells as previously described [82]. For
in vitro multistep growth curves, 3T12 cells were infected at a MOI of
0.05. Samples were harvested at various time points postinfection,
subjected to three freeze-thaw cycles, mechanically disrupted with 1
mm silica beads, and titered by plaque assay [36].
In vivo infection. Mice were intraperitoneally injected with 10
6
PFU of virus in 0.5 ml of D10. For acute titers, half a spleen and half a
lobe of liver per mouse were mechanically disrupted with 1 mm silica
beads and titered by plaque assay [81]. Data represent the mean 6
SEM from at least two independent experiments, and statistical
signiﬁcance was determined using the Mann-Whitney test. For ex vivo
reactivation, peritoneal cells pooled from 3–5 mice per experimental
group were plated in serial 2-fold dilutions onto MEF monolayers,
which were assessed for cytopathic effect caused by reactivated virus
after 21 d. Persistent replication was analyzed by quantitating
preformed infectious virus in mechanically disrupted cells, which
cannot reactivate virus [83]. Data represent the mean 6 SEM from at
least three independent experiments, and were analyzed by nonlinear
regression using GraphPad Prism (GraphPad Software, San Diego,
California, United States). The frequency of cells that reactivated
virus ex vivo was determined by calculating the cell density at which
63.2% of wells were positive for cytopathic effect. Statistical
signiﬁcance was determined using a paired t-test.
v-Bcl-2 expression and puriﬁcation. Wild-type and SGR/AAA v-Bcl-
2 used in NMR studies were expressed in E. coli BL21(DE3) strain
grown on M9 media. For wild-type v-Bcl-2, uniformly
15N-labeled,
uniformly
15N,
13C-labeled, and uniformly
15N,
13C-labeled,
75%
2Hsampleswerepreparedwithmediacontainingeither
15NH4Cl,
15NH4Cl plus [U-
13C]glucose or
15NH4Cl, [U-
13C]glucose, and 75%
2H2O, respectively. For SGR/AAA v-Bcl-2, a
15N-labeled sample was
prepared with media containing
15NH4Cl as the sole nitrogen source.
Soluble protein was puriﬁed by Ni
2þ-afﬁnity chromatography. NMR
samples contained 0.5–1.0 mM protein in either 90% H2O with 10%
2H2O or 100%
2H2O, 20 mM
2H-TRIS (pH 7.8), and 5 mM
2H-
dithiothreitol.
NMR spectroscopy. All NMR experiments were acquired at 303 K
on a Bruker DRX500, DRX600 or DRX800 NMR spectrometer.
Backbone
1H,
13C, and
15N resonance assignments were achieved with
(
15N,
13C,[75%]
2H) cHV68 v-Bcl-2 using a suite of deuterium-
decoupled, triple-resonance experiments (HNCA, HN[CO]CA,
HN[CA]CB, HN[COCA]CB, HNCO and HN[CA]C) [84,85]. Side-chain
1H and
13C NMR signals were assigned from HCCH-TOCSY experi-
ments [86]. Stereospeciﬁc assignments of valine and leucine methyl
groups were obtained from an analysis of the
13C-
13C coupling
patterns observed for biosynthetically directed, fractionally
13C-
labeled cHV68 v-Bcl-2 [87]. NOE distance restraints were obtained
from three-dimensional
15N- and
13C-edited NOESY spectra [88,89]
acquired with a mixing time of 80 ms. Slowly exchanging amide
protons were identiﬁed in an
15N-HSQC spectrum recorded imme-
diatelyafter exchanging the protein into a buffer prepared with
2H2O.
Structure calculations. v-Bcl-2 structures were calculated using a
simulated annealing protocol [90] with the program CNX (MSI, San
Diego, California, United States). A square-well potential (FNOE ¼
50 kcal mol
 1) was employed to constrain NOE-derived distances.
Based on cross-peak intensities, NOE-derived distance restraints
were given upper bounds of 3.5, 4.5, or 6.0 H. In the reﬁnement
stage, additional ambiguous constraints were added, with an upper
bound of 6.0 H, for unassigned cross peaks that were consistent
with the chemical shift table (i.e., error bars of 0.07 ppm for
protons and 0.7 ppm for hetero atoms) and the structure. Torsion
angle restraints, / and w, were generated from analysis of N, C9,
C
a, and H
a chemical shifts using the TALOS program [91]. A force
constant of 200 kcal mol
 1rad
 2 was applied to all torsional
restraints. Explicit hydrogen bonds were included in a-helices only
for residues observed to have slowly exchanging amide protons.
The program PROCHECK was employed to analyze the geometric
quality of the calculated structures in the ensemble [92].
Peptide binding. Binding of the Bak 16-mer (GQVGRQLAIIGD-
DINR), the Bax 16-mer (KKLSECLKRIGDELDS), the Bad 25-mer
(NLWAAQRYGRELRRMSDEFVSFKK), and a D83A mutant Bak 16-
mer (GQVGRQLAIIGADINR) to wild-type v-Bcl-2, and binding of
the Bax 16-mer to SGR/AAA v-Bcl-2 was assessed by NMR titration
[93]. Each peptide was titrated from a concentrated stock solution
into a sample of
13C-labeled protein, and binding was monitored
from changes in a
13C methyl-HSQC spectrum [93]. For wild-type v-
Bcl-2,
13C-HSQC spectra were recorded on a uniformly
13C,
15N-
labeled protein sample (120 lM) in the presence of increasing
amounts of peptide (40, 80, 160, 240, and 320 lM). For SGR/AAA v-
Bcl-2,
15N-HSQC spectra were recorded on a sample of uniformly
15N-labeled protein in the presence of increasing amounts of
peptide.
Supporting Information
Figure S1. v-Bcl-2 Inhibits Cell Death in Thymocytes
Representative dot plots showing CD4 and CD8 proﬁles of non-
transgenic or v-Bcl-2 transgenic thymocytes after no treatment or
treatment with 0.3 mg of dexamethasone, 250 rads of c-irradiation, or
30 lg of anti-CD3e antibody.
Found at DOI: 10.1371/journal.ppat.0010010.sg001 (174 KB PDF).
Figure S2. Solution Structure of cHV68 v-Bcl-2
Ribbon representations of (A) cHV68 v-Bcl-2 and (B) Bcl-xL. Helices
are numbered with respect to Bcl-xL. The BH1, BH2, BH3, and BH4
regions are colored magenta, red, green and yellow, respectively.
Connolly surface for (C) cHV68 v-Bcl-2 and (D) Bcl-xL.T h e
Connolly surface was calculated using a probe radius of 1.4 A ˚ .
Residues are colored as follows: Leu, Val, Ile, Phe, Tyr, Trp, Met, and
Ala are yellow; Arg, Lys, and His are blue; Asp and Glu are red; and
all other residues are gray. Black arrows indicate the hydrophobic
grooves present on the surfaces of Bcl-xL and cHV68 v-Bcl-2.
Found at DOI: 10.1371/journal.ppat.0010010.sg002 (5.3 MB PDF).
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